Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.

Provided is a novel metal complex that can be used as an electron transporting material. A metal complex represented by the following Formula (1) to the following Formula (3). R.sup.A1 to R.sup.A9, R.sup.C1 to R.sup.C8, and R.sup.E1 to R.sup.E6 are each independently a single bond, an alkylene group, an arylene group, a heteroarylene group, or a group represented by —R.sup.P1—P(═O)R.sup.P2—R.sup.P3—, R.sup.B1 to R.sup.B9, R.sup.D1 to R.sup.D8, and R.sup.F1 to R.sup.F6 are each independently a hydrogen atom, an. alkyl group, an aryl group, a heteroaryl group, an alkoxy group, an aryloxy group, a heteroaryloxv group, an amino group, a cyano group, a halogen atom, or a hydroxy group, one or more selected from the group consisting of R.sup.B1 to R.sup.B9 are a phenanthrolinyl group, one or more selected from the group consisting of R.sup.D1 to R.sup.D8 are a phenanthrolinyl group, and one or more selected from the group consisting of R.sup.F1 to R.sup.F6 are a phenanthrolinyl group, M is an alkali metal or an alkaline earth metal, Z is 1 or 2, and X is O or S.

Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

The present invention relates to compounds comprising a benzimidazole scaffold, and the use of such compounds for the treatment of viral diseases. The invention also relates to pharmaceutical compositions comprising said compounds as an active ingredient. In particular the compounds of the invention comprising a benzimidazole scaffold are used for the treatment of filoviruses or retroviruses, and preferably for the treatment of Ebola virus or HIV virus.

The present invention provides compounds, compositions thereof, and methods of using the same.

A method for treating patients with viral infections, particularly coronavirus infections, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of any one of formulas (I)-(VI) or Compound 1, 2, 3, 4, or 5, or a pharmaceutically acceptable salt thereof.

The present invention relates to novel substituted bicyclic derivatives that can inhibit Rho-kinases and/or Rho-kinase mediated phosphorylation of myosin light chain phosphates, compositions comprising the derivatives, methods for preparing the derivatives, and methods for using the derivatives and/or compositions.

Pyrimidine compounds of formula (I) shown herein. Also disclosed are pharmaceutical compositions containing one of the pyrimidine compounds and methods of using the pyrimidine compounds to treat or prevent chemotherapy-induced peripheral neuropathy.

The invention relates to a marking precursor incorporating a chelator or fluorination group for radiolabelling with .sup.44Sc, .sup.47Sc, .sup.55Co, .sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.66Ga, .sup.67Ga, .sup.68Ga, .sup.89Zr, .sup.86Y, .sup.90Y, .sup.90Nb, .sup.99mTc, .sup.111In, .sup.135Sm, .sup.140Pr, .sup.159Gd, .sup.149Tb, .sup.160Tb, .sup.161Tb, .sup.165Er, .sup.166Dy, .sup.166Ho, .sup.175Yb, .sup.177Lu, .sup.186Re, .sup.188Re, .sup.213Bi and .sup.225Ac or with .sup.18F, .sup.131I or .sup.211At, and one or two biological targeting vectors which are coupled to the chelator or fluorinating group via one or more squaric acid groups.

Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I):

##STR00001##

or a stereoisomer, tautomer or salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, L.sup.1, L.sup.2, L.sup.3, L.sup.4, M, m and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.